IBRO Neuroscience Reports
October 1, 2023
Prateep Sanker Beed, Dietmar Schmitz
This April will be the 80th anniversary of the discovery of LSD by Albert Hofmann. The so-called 'problem child' of his has come a long way to maturity yet many aspects are unknown. Off late there has been a resurgence in psychedelics research as substances like LSD show promise as therapeutics and also reveal insights about our sensory and cognitive processing. We deconstructed the reported...
Psychological Medicine
October 1, 2023
Jonathan W. Kanen, Qiang Luo, Mojtaba Rostami Kandroodi et al.
44 citations
The non-selective serotonin 2A (5-HT2A) receptor agonist lysergic acid diethylamide (LSD) holds promise as a treatment for some psychiatric disorders. Psychedelic drugs such as LSD have been suggested to have therapeutic actions through their effects on learning. The behavioural effects of LSD in humans, however, remain incompletely understood. Here we examined how LSD affects probabilistic...
Social Psychiatry and Psychiatric Epidemiology
October 1, 2023
Nicholas L. Bormann, Andrea N Weber, Benjamin Miskle et al.
6 citations
Psychedelics are being explored for their potential therapeutic benefits across a wide range of psychiatric diagnoses and may usher in a new age in psychiatric treatment. There is stigma associated with these currently illegal substances, and use varies by race and age. We hypothesized that minoritized racial and ethnic populations, relative to White respondents, would perceive psychedelic use...
Neuropsychopharmacology
October 1, 2023
Tim Hirschfeld, Johanna Prugger, Tomislav Majić et al.
24 citations
Lysergic acid diethylamide (LSD) is a potent classic serotonergic psychedelic, which facilitates a variety of altered states of consciousness. Here we present the first meta-analysis establishing dose-response relationship estimates of the altered states of consciousness induced by LSD. Data extracted from articles identified by a systematic literature review following PRISMA guidelines were...
Neuropsychopharmacology
October 1, 2023
Laura Ley, Friederike Holze, Denis Arikci et al.
127 citations
Mescaline, lysergic acid diethylamide (LSD), and psilocybin are classic serotonergic psychedelics. A valid, direct comparison of the effects of these substances is lacking. The main goal of the present study was to investigate potential pharmacological, physiological and phenomenological differences at psychoactive-equivalent doses of mescaline, LSD, and psilocybin. The present study used a...
Biological Psychiatry
September 15, 2023
Robin J Murphy, Rachael Sumner, William Evans et al.
69 citations
Microdosing psychedelic drugs is a widespread social phenomenon with diverse benefits claimed for mood and cognition. Randomized controlled trials have failed to support these claims, but the laboratory-based dosing in trials conducted to date may have limited ecological validity. Healthy male volunteers were randomized into lysergic acid diethylamide (LSD) (n = 40) and placebo (n = 40) groups...
The Brown University Psychopharmacology Update
September 3, 2023
Vitamin D3, omega-3s show no protection against late-life depression Some older adults with subthreshold depression or at high risk for depression might have elevated inflammation or poor vascular and metabolic health, suggesting that supplementation could improve mood in these individuals. An ancillary study to a trial of vitamin D3 and omega-3 fatty acids examined the effects of these...
September 1, 2023
Aldo Chiquini
La microdosificación (o las microdosis) hace referencia al ingerir una dosis muy baja de una sustancia psicodélica, donde no hay efectos de alteraciones cognitivas, afectivas, perceptivas y neurofisiológicas. Recientemente instituciones como la MAPS, la Universidad Johns Hopkins, el Imperial College of London y la FDA, a dicha microdosificación le han designado como «terapia innovadora», ya que...
CNS Drugs
September 1, 2023
Antonio Inserra, Alexandre Piot, Danilo de Gregorio et al.
17 citations
Anxiety disorders (ADs) represent the sixth leading cause of disability worldwide, resulting in a significant global economic burden. Over 50% of individuals with ADs do not respond to standard therapies, making the identification of more effective anxiolytic drugs an ongoing research priority. In this work, we review the preclinical literature concerning the effects of lysergic acid...
Journal of Psychoactive Drugs
August 31, 2023
Alexsandra Kovacevich, Jeremy Weleff, Benjamin Claytor et al.
6 citations
Cultural awareness of anosmia and microsmia has recently increased due to their association with COVID-19, though treatment for these conditions is limited. A growing body of online media claims that individuals have noticed improvement in anosmia and microsmia following classic psychedelic use. We report what we believe to be the first three cases recorded in the academic literature of...